Soluble tumor necrosis factor-tumor necrosis factor receptor 1 signaling complex (sTNF-TNFR1) (sTNF-TNFR1 complex)

The soluble tumor necrosis factor-tumor necrosis factor receptor 1 (sTNF-TNFR1) signaling complex is a pivotal mediator of systemic inflammation and programmed cell death pathways, including apoptosis and necroptosis [1, 2]. TNF-alpha is initially expressed as a transmembrane protein (tmTNF) and is subsequently cleaved by the TNF-alpha converting enzyme (TACE) to release its soluble form (sTNF), which exhibits a high affinity for TNFR1 [3]. Once formed, this complex initiates the recruitment of intracellular adaptor proteins such as TRADD and RIPK1, triggering the NF-kappaB signaling cascade and the production of various pro-inflammatory cytokines [2, 3]. Chronic or excessive activation of the sTNF-TNFR1 axis is strongly associated with the pathogenesis of autoimmune disorders like rheumatoid arthritis and neurodegenerative diseases such as Alzheimer's and Parkinson's [4]. While conventional TNF inhibitors (e.g., adalimumab, etanercept) neutralize both sTNF and tmTNF, emerging therapeutic strategies focus on the selective inhibition of sTNF or the antagonism of TNFR1 [4, 5]. This selective approach is designed to mitigate chronic inflammation while preserving the essential homeostatic and host-defense functions provided by tmTNF and TNFR2 signaling [3, 5].

Other names

sTNF-TNFR1 axisSoluble TNF-TNFRSF1A complexTNFR1 signaling complexsTNF-TNFR1 signaling pathway

Neutralization of soluble TNF or selective antagonism of the TNFR1 receptor to inhibit the formation of the pro-inflammatory signaling complex, thereby reducing NF-kappaB activation and apoptosis while preserving transmembrane TNF-mediated signaling.